TOP2A overexpression in these cancers is associated with aberrant cell proliferation, aneuploidy, an aggressive tumor phenotype, advanced disease stage, tumor recurrence, and decreased overall survival (Doussis‐Anagnostopoulou et al., 2008; Faggad et al., 2009; Jarvinen et al., 1996; Kalogeraki et al., 2005; Lan et al., 2014; Nakopoulou et al., 2000; Zhao et al., 2008). This evidence concerns the gene TOP2A and cancer.